The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer …
Objectives The irreversible epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR TKIs) afatinib and dacomitinib are approved for first-line treatment of EGFR mutation …
(EGFR TKIs) afatinib and dacomitinib are approved for first-line treatment of EGFR mutation …
Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis
W Zhang, Y Wei, D Yu, J Xu, J Peng - Medicine, 2018 - journals.lww.com
Background: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …
Ritonavir and efavirenz significantly alter the metabolism of erlotinib—an observation in primary cultures of human hepatocytes that is relevant to HIV patients with …
VC Pillai, R Venkataramanan, RA Parise… - Drug Metabolism and …, 2013 - ASPET
Erlotinib is approved for the treatment of non–small cell lung and pancreatic cancers, and is
metabolized by CYP3A4. Inducers and inhibitors of CYP3A enzymes such as ritonavir and …
metabolized by CYP3A4. Inducers and inhibitors of CYP3A enzymes such as ritonavir and …
[HTML][HTML] Prevalence of acute oral mucosal damage secondary to the use of systemic antineoplastics: A systematic review and meta-analysis
ME Rodríguez-Fuentes, M Pérez-Sayáns… - Oral Surgery, Oral …, 2023 - Elsevier
Objective The aim of this study was to determine the prevalence of acute oral mucosal
toxicities in non-irradiated patients treated with systemic antineoplastics agents. The …
toxicities in non-irradiated patients treated with systemic antineoplastics agents. The …
Adverse events of targeted therapies
JA Klastersky - Current opinion in oncology, 2014 - journals.lww.com
Targeted therapies are associated with a wide spectrum of adverse events, which cannot
always be easily separated from the complications linked to cancer, its therapy, and …
always be easily separated from the complications linked to cancer, its therapy, and …
Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy
EJ Searle, TM Illidge, IJ Stratford - Clinical Oncology, 2014 - Elsevier
Recent drug discovery developments in the field of small molecule targeted agents have led
to much interest in combining these with radiotherapy. There are good preclinical data to …
to much interest in combining these with radiotherapy. There are good preclinical data to …
Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity
K Yonesaka, T Suzumura, H Tsukuda… - Anticancer …, 2014 - ar.iiarjournals.org
Aim: To evaluate the tolerability and efficacy of erlotinib treatment in advanced non-small
cell lung cancer (NSCLC) patients who had previously experienced severe hepatotoxicity …
cell lung cancer (NSCLC) patients who had previously experienced severe hepatotoxicity …
Kovalent‐allosterische Kinase‐Inhibitoren
J Weisner, R Gontla, L van der Westhuizen… - Angewandte …, 2015 - Wiley Online Library
Proteinkinasen repräsentieren wichtige Knotenpunkte intrazellulärer Signalwege und sind
somit an vielen physiologischen und pathologischen Prozessen beteiligt. Konformations …
somit an vielen physiologischen und pathologischen Prozessen beteiligt. Konformations …
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer
M Zaarour, C Weerasinghe, B Nazha… - Expert Review of …, 2015 - Taylor & Francis
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths
worldwide. At diagnosis, half of the patients are over 70 years of age, and most present with …
worldwide. At diagnosis, half of the patients are over 70 years of age, and most present with …
Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases
B Shriyan, D Patil, M Gurjar, M Nookala, A Patil… - European Journal of …, 2020 - Springer
Purpose Patients of non–small cell lung cancer (NSCLC) with brain metastases have limited
treatment options. High-dose erlotinib (HDE) and gefitinib (HDG) have been tried in the past …
treatment options. High-dose erlotinib (HDE) and gefitinib (HDG) have been tried in the past …